

## **Aptar Active Material Science Secures USPTO Allowance for N-Sorb<sup>SM</sup> Technology, Establishing First-of-Its-Kind Packaging-Delivered Approach to Nitrosamine Risk Mitigation**

***Company's N-Sorb<sup>SM</sup> technology IP uniquely integrates material science innovation with demonstrated performance on drug products.***

Auburn, Alabama, June 9, 2026— **Aptar Active Material Science**, part of AptarGroup, Inc. and a global leader in active material science solutions, has announced a significant intellectual property milestone in its nitrosamine risk mitigation platform. The company's foundational U.S. patent application for its **N-Sorb<sup>SM</sup> technology** has been approved by the United States Patent and Trademark Office (USPTO).

The achievement represents a critical advancement for the pharmaceutical industry, as the N-Sorb<sup>SM</sup> technology IP uniquely integrates material science innovation with demonstrated performance on drug products. As a result, the technology establishes a new standard for packaging-delivered mitigation of nitrosamine impurities.

N-Sorb<sup>SM</sup> technology can be deployed across multiple packaging configurations, including blister systems, bottle formats (including drop-in solutions), and film-based structures, enabling integration without changes to formulation or manufacturing processes. The patent application encompasses both the proprietary material composition and validated reduction of nitrosamines across multiple active pharmaceutical ingredients (APIs) known to exhibit nitrosamine vulnerability. This extends the N-Sorb<sup>SM</sup> technology platform beyond traditional packaging IP into performance-driven protection.

Importantly, the patent application includes provisions that can support potential listing in the FDA Orange Book, a public registry of all FDA-approved drugs based on safety and effectiveness. The patent application demonstrates the technology's performance on drug products within the scope of the claims. Additionally, the application explicitly names many APIs with nitrosamine susceptibility. As such, pharmaceutical partners utilizing N-Sorb<sup>SM</sup> technology may have the opportunity to pursue enhanced regulatory and commercial protection strategies tied to finished product performance.

“This milestone marks a fundamental shift in how the industry can address nitrosamine risk,” said Badre Hammond, VP, Global Commercial Operations and GM, APAC for Aptar

Active Material Science. “For the first time, we are bringing together advanced material science and demonstrated drug product performance within a single IP framework. That combination creates a powerful new lever for our pharmaceutical partners to mitigate risk and establish differentiated regulatory and commercial positions (i.e. Orange Book listing). This is a platform innovation with broad implications for product integrity, lifecycle management, and patient safety.”

In August 2024, N-Sorb<sup>SM</sup> technology was accepted to the U.S. Food & Drug Administration’s (FDA) highly selective [Emerging Technology Program \(ETP\)](#), which aims to identify and resolve potential technical and regulatory issues related to novel technologies prior to regulatory submission. The program promotes the adoption of innovative approaches to product design and manufacturing, facilitating industry modernization and reducing timeframes and costs for introducing novel solutions.

###

## **About Aptar Active Material Science**

Aptar Active Material Science is part of AptarGroup, Inc., a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar Active Material Science leverages its active material science expertise to transform ideas into market opportunities, accelerate and de-risks the product development process, and provide complete solutions that improve consumers’ and patients’ lives. The company offers a complete set of services from concept ideation, to design and engineering, to product development, global production, quality control, and regulatory support that results in expedited speed-to-market. For more information, please visit [www.csptechnologies.com](http://www.csptechnologies.com) and [www.aptar.com](http://www.aptar.com)

